18th August 2025
25th June 2025
āshibio Doses First Patient in Phase 1b Trial of Andecaliximab in Patients with Spinal Cord Injury (SCI) at Risk of Heterotopic Ossification (HO)
4th June 2025
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
28th May 2025
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
28th May 2025
Aktis Oncology Initiates Phase 1b Clinical Trial Of Its Nectin-4- Targeting Radiopharmaceutical Product Candidate, Aky-1189, Across Multiple Tumor Types
31st March 2025
Orna Therapeutics Appoints Joseph Bolen, Ph.D., an MPM BioImpact Entrepreneur Partner, as Chief Executive Officer
29th January 2025
Cullinan Therapeutics Announces Primary Endpoint Met in Phase 2b Trial of Zipalertinib
7th January 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
1st October 2024
AstronauTx Appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
30th September 2024